Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/update-on-lung-cancer-from-the-annual-meeting-of-the-american-society-zPpIjvz5OX
References (42)
-
B. Hellerstedt, G. Edelman, N. Vogelzang, H. Kluger, C. Yasenchak, Xiao-dong Shen, D. Ramies, M. Gordon, P. Lara (2012)
Activity of cabozantinib (XL184) in metastatic NSCLC: Results from a phase II randomized discontinuation trial (RDT).Journal of Clinical Oncology, 30
-
B. Davies, A. Logié, J. McKay, Paul Martin, Samantha Steele, R. Jenkins, Mark Cockerill, S. Cartlidge, Paul Smith (2007)
AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical modelsMolecular Cancer Therapeutics, 6
-
D. Eberhard, B. Johnson, L. Amler, A. Goddard, Sherry Heldens, R. Herbst, William Ince, P. Jänne, T. Januario, David Johnson, P. Klein, V. Miller, M. Ostland, D. Ramies, Dragan Sebisanovic, Jeremy Stinson, Yu Zhang, S. Seshagiri, K. Hillan (2005)
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 25
-
T Winton, R Livingston, D Johnson, J Rigas, M Johnston, C Butts (2005)
Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancerN Engl J Med, 352
-
A. Shaw, D. Camidge, J. Engelman, B. Solomon, E. Kwak, J. Clark, R. Salgia, G. Shapiro, Y. Bang, Weiwei Tan, L. Tye, K. Wilner, P. Stephenson, M. Varella-Garcia, K. Bergethon, A. Iafrate, S. Ou (2012)
Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement.Journal of Clinical Oncology, 30
-
F. Shepherd, A. Bourredjem, E. Brambilla, C. Domerg, J. Douillard, M. Filipits, S. Graziano, P. Hainaut, P. Jänne, T. Chevalier, G. Teuff, J. Pignon, R. Pirker, L. Seymour, J. Soria, M. Taron, M. Tsao (2012)
Prognostic and predictive effects of KRAS mutation subtype in completely resected non-small cell lung cancer (NSCLC): A LACE-bio study.Journal of Clinical Oncology, 30
-
W. Pao, Theresa Wang, Gregory Riely, V. Miller, Qiulu Pan, M. Ladanyi, M. Zakowski, R. Heelan, M. Kris, H. Varmus (2005)
KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or ErlotinibPLoS Medicine, 2
-
R. Lilenbaum, M. Zukin, J. Pereira, Carlos Barrios, Ronaldo Ribeiro, C. Beato, Yeni Nascimento, A. Murad, Fabio Franke, M. Precivale, L. Araújo, Clarissa Baldotto, Fernando Vieira, I. Small, C. Ferreira (2012)
A randomized phase III trial of single-agent pemetrexed (P) versus carboplatin and pemetrexed (CP) in patients with advanced non-small cell lung cancer (NSCLC) and performance status (PS) of 2.Journal of Clinical Oncology, 30
-
R. Doebele, Amanda Pilling, D. Aisner, T. Kutateladze, A. Le, A. Weickhardt, K. Kondo, Derek Linderman, L. Heasley, W. Franklin, M. Varella-Garcia, R. Camidge (2012)
Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung CancerClinical Cancer Research, 18
-
R. Pirker, J. Pereira, J. Pawel, M. Krzakowski, R. Ramlau, Keunchil Park, F. Marinis, W. Eberhardt, L. Paz-Ares, S. Störkel, K. Schumacher, A. Heydebreck, I. Celik, K. O'Byrne (2012)
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.The Lancet. Oncology, 13 1
-
T. Ciuleanu, L. Stelmakh, S. Cicėnas, S. Miliauskas, A. Grigorescu, C. Hillenbach, H. Johannsdottir, B. Klughammer, E. González (2012)
Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.The Lancet. Oncology, 13 3
-
D. Camidge, M. Skokan, Porntip Kiatsimkul, B. Helfrich, Nathan Schulte, Delee Maxson, D. Aisner, W. Franklin, R. Doebele, M. Varella-Garcia (2012)
Native and rearranged ALK copy number and rearranged ALK cell count in NSCLC: Implications for ALK inhibitor therapy.Journal of Clinical Oncology, 30
-
K. Furuse, M. Fukuoka, M. Kawahara, H. Nishikawa, Y. Takada, S. Kudoh, N. Katagami, Y. Ariyoshi (1999)
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 17 9
-
J. Yang, J. Shih, W. Su, T. Hsia, C. Tsai, S. Ou, Chung-Jen Yu, G. Chang, C. Ho, L. Sequist, A. Dudek, M. Shahidi, X. Cong, R. Lorence, Pan‐Chyr Yang, V. Miller (2012)
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.The Lancet. Oncology, 13 5
-
Satomi Yamamoto, K. Tsujino, M. Ando, T. Kawaguchi, A. Kubo, S. Isa, Y. Hasegawa, S. Ou, M. Takada, T. Kurata (2012)
Is consolidation chemotherapy after concurrent chemoradiotherapy beneficial for locally advanced non-small cell lung cancer? A pooled analysis of the literature.Journal of Clinical Oncology, 30
-
Edward Kim, M. Neubauer, A. Cohn, L. Schwartzberg, L. Garbo, J. Caton, F. Robert, T. Katz, S. Chittoor, L. Simms, S. Saxman (2012)
SELECT: Randomized phase III study of docetaxel (D) or pemetrexed (P) with or without cetuximab (C) in recurrent or progressive non-small cell lung cancer (NSCLC) after platinum-based therapy.Journal of Clinical Oncology, 30
-
K. Takeuchi, M. Soda, Yuki Togashi, R. Suzuki, S. Sakata, S. Hatano, R. Asaka, W. Hamanaka, H. Ninomiya, H. Uehara, Y. Choi, Y. Satoh, S. Okumura, K. Nakagawa, H. Mano, Y. Ishikawa (2012)
RET, ROS1 and ALK fusions in lung cancerNature Medicine, 18
-
U. McDermott, A. Iafrate, N. Gray, T. Shioda, M. Classon, S. Maheswaran, Wenjun Zhou, H. Choi, Shannon Smith, L. Dowell, L. Ulkus, Georgiana Kuhlmann, Patricia Greninger, J. Christensen, D. Haber, J. Settleman (2008)
Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.Cancer research, 68 9
-
S. Senan, N. Verstegen, D. Palma, G. Rodrigues, F. Lagerwaard, A. Elst, R. Mollema, W. Tets, A. Warner, J. Joosten, M Amir, C. Haasbeek, E. Smit, B. Slotman, J. Oosterhuis (2012)
Stages I-II non-small cell lung cancer treated using either lobectomy by video-assisted thoracoscopic surgery (VATS) or stereotactic ablative radiotherapy (SABR): Outcomes of a propensity score-matched analysis.Journal of Clinical Oncology, 30
-
N. Hanna (2006)
Vinorelbine Plus Cisplatin vs Observation in Resected Non–Small-Cell Lung CancerYearbook of Medicine, 2006
-
outcomes of a propensity score-matched analysis -
M. Salido, L. Pijuan, L. Martínez‐Avilés, A. Galván, I. Canadas, A. Rovira, M. Zanui, Alejandro Martinez, R. Longarón, F. Solè, S. Serrano, B. Bellosillo, M. Wynes, J. Albanell, F. Hirsch, E. Arriola (2011)
Increased ALK Gene Copy Number and Amplification are Frequent in Non-small Cell Lung CancerJournal of Thoracic Oncology, 6
-
J. Brahmer, L. Horn, S. Antonia, D. Spigel, L. Gandhi, L. Sequist, J. Wigginton, D. McDonald, G. Kollia, A. Gupta, S. Gettinger (2012)
Clinical activity and safety of anti-PD1 (BMS-936558, MDX-1106) in patients with advanced non-small-cell lung cancer (NSCLC).Journal of Clinical Oncology, 30
-
Dong-Wan Kim, M. Ahn, Yuankai Shi, T. Pas, Pan‐Chyr Yang, Gregory Riely, L. Crinò, T. Evans, Xiaoqing Liu, Ji-Youn Han, R. Salgia, D. Moro-Sibilot, S. Ou, S. Gettinger, Yi-long Wu, S. Lanzalone, A. Polli, S. Iyer, A. Shaw (2012)
Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC).Journal of Clinical Oncology, 30
-
A. Tsao (2012)
ROS1 Rearrangements Define a Unique Molecular Class of Lung CancersYearbook of Oncology, 2012
-
P. Zatloukal, L. Petruželka, M. Zemanova, L. Havel, F. Janku, L. Judas, A. Kubík, E. Křepela, P. Fiala, L. Pecen (2004)
Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study.Lung cancer, 46 1
-
M. Garassino, O. Martelli, A. Bettini, I. Floriani, E. Copreni, C. Lauricella, M. Ganzinelli, M. Marabese, M. Broggini, S. Veronese, G. Gherardi, F. Longo, M. Fabbri, M. Tomirotti, O. Alabiso, M. Sarobba, R. Labianca, S. Marsoni, G. Farina, Alberto Scanni (2012)
TAILOR: Phase III trial comparing erlotinib with docetaxel in the second-line treatment of NSCLC patients with wild-type (wt) EGFR.Journal of Clinical Oncology, 30
-
T. Yeh, V. Marsh, B. Bernat, J. Ballard, Heidi Colwell, R. Evans, Janet Parry, Darin Smith, B. Brandhuber, S. Gross, A. Marlow, Brian Hurley, J. Lyssikatos, Patrice Lee, J. Winkler, K. Koch, E. Wallace (2007)
Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 InhibitorClinical Cancer Research, 13
-
Dong-Wan Kim, M. Ahn, P-C. Yang, X. Liu, T. Pas, L. Crinò, S. Lanzalone, A. Polli, A. Shaw (2012)
Updated Results of a Global Phase II Study with Crizotinib in Advanced Alk-Positive Non-Small Cell Lung Cancer (NSCLC)Annals of Oncology, 23
-
P. Jänne, A. Shaw, J. Pereira, G. Jeannin, J. Vansteenkiste, C. Barrios, F. Franke, L. Grinsted, Paul Smith, V. Zazulina, I. Smith, L. Crinò (2012)
Phase II double-blind, randomized study of selumetinib (SEL) plus docetaxel (DOC) versus DOC plus placebo as second-line treatment for advanced KRAS mutant non-small cell lung cancer (NSCLC).Journal of Clinical Oncology, 30
-
L. Paz-Ares, F. Marinis, M. Dediu, Michael Thomas, J. Pujol, P. Bidoli, O. Molinier, T. Sahoo, E. Laack, M. Reck, J. Corral, S. Melemed, W. John, N. Chouaki, A. Zimmermann, C. Visseren-Grul, C. Gridelli (2012)
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.The Lancet. Oncology, 13 3
-
M. Schuler, N. Yamamoto, K. O'Byrne, V. Hirsh, T. Mok, Sarayut Geater, S. Orlov, C. Tsai, M. Boyer, W. Su, J. Bennouna, T. Kato, V. Gorbunova, K. Lee, R. Shah, D. Massey, R. Lorence, M. Shahidi, L. Sequist (2012)
LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 18_suppl
-
K Bergethon, AT Shaw, SH Ou, R Katayama, CM Lovly, NT McDonald (2012)
ROS1 rearrangements define a unique molecular class of lung cancersJ Clin Oncol., 30
-
J. Pignon, H. Tribodet, G. Scagliotti, J. Douillard, F. Shepherd, R. Stephens, A. Dunant, V. Torri, R. Rosell, L. Seymour, S. Spiro, E. Rolland, R. Fossati, D. Aubert, K. Ding, D. Waller, T. Chevalier (2008)
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 21
-
implications for ALK inhibitor therapy -
a LACE-bio study -
RM Huber, W Engel-Riedel, J Kollmeier, S Andreas, S Staar, G Klautke (2012)
III non-small cell lung cancer (NSCLC): final results of a phase (ph) III studyJ Clin Oncol, 30
-
Ana Pot, D. Qing, ss Camidge, S. Kono, A. Flacco, A. Tan, R. Doebele, L. Crinò, W. Franklin, M. Varella-Garcia (2010)
Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor TreatmentClinical Cancer Research, 16
-
C. Mascaux, N. Iannino, B. Martin, M. Paesmans, T. Berghmans, Michèle Dusart, A. Haller, P. Lothaire, A. Meert, S. Noël, J. Lafitte, J. Sculier (2004)
The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysisBritish Journal of Cancer, 92
-
A. Cohn, R. Kelley, T.S. Yang, W. Su, C. Verslype, D. Ramies, Yihua Lee, Xiao-dong Shen, E. Cutsem (2012)
Activity of cabozantinib (XL184) in hepatocellular carcinoma patients (pts): Results from a phase II randomized discontinuation trial (RDT).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 4_suppl
-
O. Martelli, A. Bettini, I. Floriani, E. Copreni, C. Lauricella, M. Ganzinelli, M. Marabese, M. Broggini, S. Veronese, G. Gherardi, F. Longo, M. Fabbri, M. Tomirotti, O. Alabiso, M. Sarobba, R. Labianca, S. Marsoni, G. Farina, A. Scanni (2012)
TAILOR: A phase III trial comparing erlotinib with docetaxel as the second-line treatment of NSCLC patients with wild-type (wt) EGFR.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 18_suppl
-
Y. Suehara, M. Arcila, A. Drilon, Tatsuo Ito, Lu Wang, Adnan Hasanovic, R. Khanin, N. Rizvi, M. Ladanyi (2012)
KIF5B-RET: Discovery of a novel fusion oncogene in lung adenocarcinomas by a systematic screen for tyrosine kinase fusions and identification of patients for a RET targeted therapy trial.Journal of Clinical Oncology, 30
- Publisher
- Springer Journals
- Copyright
- Copyright © 2012 by Springer-Verlag Wien
- Subject
- Medicine & Public Health; Oncology; Medicine/Public Health, general
- ISSN
- 1865-5041
- eISSN
- 1865-5076
- DOI
- 10.1007/s12254-012-0050-z
- Publisher site
- See Article on Publisher Site
Abstract
The American Society of Clinical Oncology (ASCO) held its annual meeting in Chicago, Illinois (USA) from June 1–5, 2012. In the lung cancer track, several hundreds of abstracts were presented. The following article will give an overview on some interesting and relevant abstracts. Beside new drugs, the role of biomarker, and maintenance therapy, we will also discuss issues on early-stage disease.
Journal
memo - Magazine of European Medical Oncology – Springer Journals
Published: Oct 20, 2012